Advances in 3D Printing of Biopharmaceuticals
Modern technology has enabled the development of novel dosage forms for targeted therapy. However, the fabrication of novel dosage forms at industrial scale is limited and the industry still runs on conventional drug delivery systems, especially modified tablets. The introduction of 3D printing technology in the pharmaceutical industry has opened new horizons in the research and development of printed materials and devices. The main benefits of 3D printing technology lie in the production of small batches of medicines, each with tailored dosages, shapes, sizes, and release characteristics.
Industrial and academic researchers have recently examined the use of 3D printing technologies to overcome the limitations associated with conventional manufacturing processes. These technologies involved fabrication of three-dimensional structures through additive joining of materials in a layer-by-layer manner. The introduction of 3D printing technology in the pharmaceutical industry has opened new horizons in the research and development of printed materials and devices. The main benefits of 3D printing technology lie in the production of small batches of medicines, each with tailored dosages, shapes, sizes, and release characteristics. The manufacture of medicines in this way may finally lead to the concept of personalized medicines becoming a reality.
By way of followup, this week’s available deck is titled “Advances in 3D printing of biopharmaceuticals” from Joseph Della Rocca at Merck. Joe was a past speaker at our Global Drug Bioavailability Enhancement Summit. This presentation overviews 3D printing technologies in biotechnology, 3D printed dosage forms for on-site formulation and 3D printing technology at Merck as a tool to guide formulation development. It additionally examines 3DP capsules for regional absorption studies, 3DP controlled release capsules, development of 3DP filaments for clinical use and conversion of the 3DP capsule to clinically relevant materials. To view this presentation and other novel delivery and bioavailability enhancement approaches, click below.
Our goal is to help you improve the performance of your drug products. Would you like to learn new strategies to improve patient compliance, bioavailability, stability and efficacy, all while reducing dosage, cost and decreasing time-to-market?
Join the drug development industry’s leading drug development specialists this December (9th & 10th) at the 2020 Global Drug Bioavailability Enhancement Virtual Summit. Hear from 25+ senior drug bioavailability pioneers and network with 100’s of senior drug development innovators and walk away with over 2 years of new drug formulation and bioavailability enhancement approaches strategies in just 2 short days!
Planning to attend? Register early and (save $300) or sending a group? Further group discounts available.
Join over 1450 senior drug product development professionals in our free Novel Drug Discovery & Development Group. Members of this rapidly growing group will benefit by gaining access to an exclusive network of industry and academic professionals within the drug development arena. Members specialize in discovery, development, formulation, delivery and commercialization of innovative drug products.
Want to hear multiple weekly drug product development strategies and approaches from leading organizations and experts? Subscribe here and receive new podcast episodes, presentations, white papers, tips and resources directly from Curtis & Coulter weekly to your inbox